These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15161067)

  • 1. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan.
    McNeela EA; Jabbal-Gill I; Illum L; Pizza M; Rappuoli R; Podda A; Lewis DJ; Mills KH
    Vaccine; 2004 Feb; 22(8):909-14. PubMed ID: 15161067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
    McNeela EA; O'Connor D; Jabbal-Gill I; Illum L; Davis SS; Pizza M; Peppoloni S; Rappuoli R; Mills KH
    Vaccine; 2000 Dec; 19(9-10):1188-98. PubMed ID: 11137256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.
    Mills KH; Cosgrove C; McNeela EA; Sexton A; Giemza R; Jabbal-Gill I; Church A; Lin W; Illum L; Podda A; Rappuoli R; Pizza M; Griffin GE; Lewis DJ
    Infect Immun; 2003 Feb; 71(2):726-32. PubMed ID: 12540551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.
    Huo Z; Sinha R; McNeela EA; Borrow R; Giemza R; Cosgrove C; Heath PT; Mills KH; Rappuoli R; Griffin GE; Lewis DJ
    Infect Immun; 2005 Dec; 73(12):8256-65. PubMed ID: 16299322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pluronic F127-based systemic vaccine delivery systems.
    Coeshott CM; Smithson SL; Verderber E; Samaniego A; Blonder JM; Rosenthal GJ; Westerink MA
    Vaccine; 2004 Jun; 22(19):2396-405. PubMed ID: 15193401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of LOS-specific antibody-secreting cells by ELISPOT assay].
    Jiao XA; Hirano T; Gu XX
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):366-9. PubMed ID: 15193241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine.
    Aguila A; Donachie AM; Peyre M; McSharry CP; Sesardic D; Mowat AM
    Vaccine; 2006 Jun; 24(24):5201-10. PubMed ID: 16650917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.
    Bakke H; Samdal HH; Holst J; Oftung F; Haugen IL; Kristoffersen AC; Haugan A; Janakova L; Korsvold GE; Krogh G; Andersen EA; Djupesland P; Holand T; Rappuoli R; Haneberg B
    Scand J Immunol; 2006 Mar; 63(3):223-31. PubMed ID: 16499576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system.
    Baudner BC; Morandi M; Giuliani MM; Verhoef JC; Junginger HE; Costantino P; Rappuoli R; Del Giudice G
    J Infect Dis; 2004 Mar; 189(5):828-32. PubMed ID: 14976599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
    Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization.
    Hotomi M; Ikeda Y; Suzumoto M; Yamauchi K; Green BA; Zlotnick G; Billal DS; Shimada J; Fujihara K; Yamanaka N
    Vaccine; 2005 Jan; 23(10):1294-300. PubMed ID: 15652672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant.
    Rydell N; Sjöholm I
    Vaccine; 2004 Mar; 22(9-10):1265-74. PubMed ID: 15003656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine.
    Isaka M; Komiya T; Takahashi M; Yasuda Y; Taniguchi T; Zhao Y; Matano K; Matsui H; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2004 Aug; 22(23-24):3061-8. PubMed ID: 15297056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of monophosphoryl lipid A on antibody response to diphtheria toxin and its subunits.
    Caglar K; Aybay C; Ataoglu H
    APMIS; 2005 Apr; 113(4):256-63. PubMed ID: 15865606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective nasal influenza vaccine delivery using chitosan.
    Read RC; Naylor SC; Potter CW; Bond J; Jabbal-Gill I; Fisher A; Illum L; Jennings R
    Vaccine; 2005 Aug; 23(35):4367-74. PubMed ID: 15916838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice.
    Strindelius L; Filler M; Sjöholm I
    Vaccine; 2004 Sep; 22(27-28):3797-808. PubMed ID: 15315861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
    Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
    Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.